GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Insider Ownership

Trinity Biotech (Trinity Biotech) Insider Ownership : 5.77 % (As of May. 14, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Trinity Biotech's insider ownership is 5.77%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Trinity Biotech's Institutional Ownership is 0.01%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Trinity Biotech's Float Percentage Of Total Shares Outstanding is 49.69%.


Trinity Biotech Insider Ownership Historical Data

The historical data trend for Trinity Biotech's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Insider Ownership Chart

Trinity Biotech Historical Data

The historical data trend for Trinity Biotech can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Insider Ownership 5.77 5.77 5.77 5.77 5.77 5.77 5.77 5.77 5.77 5.77

Trinity Biotech Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Trinity Biotech (Trinity Biotech) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.